Table 1 Baseline demographics and patient characteristics
Baseline characteristics | Matched (N = 59) | Non-matched (N = 54) |
|---|---|---|
Age, mean (SD), years | 51.1 (12.7) | 51.5 (10.1) |
ECOG PS baseline, n (%) | ||
0 | 36 (61) | 33 (61) |
1 | 23 (39) | 21 (39) |
RMH prognostic score, n (%) | ||
0–1 | 33 (56) | 34 (63) |
2–3 | 26 (44) | 20 (37) |
Histologic subtype, n (%) | ||
ER+/HER2− | 27 (47) | 24 (47) |
TNBC | 21 (35) | 17 (32) |
HER2+/ER+ | 8 (13) | 7 (12) |
HER2+/ER− | 3 (5) | 6 (11) |
Number sites of disease | ||
Median (range) | 3 (1–7) | 3 (1–6) |
Sites of disease, n (%) | ||
Nodal | 41 (68) | 29 (55) |
Locoregional | 29 (48) | 37 (70) |
Bone | 35 (58) | 25 (47) |
Lung | 26 (43) | 18 (34) |
Liver | 18 (30) | 20 (38) |
CNS | 0 (0) | 2 (4) |
Lines of prior therapy, median (range) | ||
Chemotherapy | 3 (0–8) | 3 (0–8) |
Endocrine therapya | 2 (1–4) | 2 (1–4) |
HER2-directed therapyb | 2 (1–4) | 2 (1–4) |
